Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 5/2005

01.05.2005 | Original Paper

Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin

verfasst von: Uwe Wollina, Gesina Hansel, Andreas Koch, Erich Köstler

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 5/2005

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Squamous cell carcinoma of the skin (SSC) is a UV-damage-related skin tumor. The first-line treatment is surgery, which has a high cure rate. In advanced cases, however, the established treatment is often not curative and shows a high rate of side effects. Improved treatment modalities are necessary.

Methods

Oral capecitabine plus subcutaneous interferon alpha were used in a prospective case series in advanced SSC of the skin at an academic teaching hospital for dermatology. Four patients with advanced SCC were included. Capecitabine 950 mgm-2 body surface on days 1 to 14 was combined with interferon alpha 3×3 mioU s.c. three times a week. The chemotherapy was repeated on day 22. Clinical response, histology, monitoring of side effects and health performance status were assessed.

Results

Four patients (two females and two males) with advanced SCC were included (age range: 19 to 75 years). Complete remission (CR) was obtained in two and partial response (PR) in two. The final outcome was CR in two and progressive disease in one. One patient died of an unknown cause. Side effects were mild. Adjuvant treatment was unnecessary. Health performance status was not affected by the treatment.

Conclusions

The treatment protocol with a combination of capecitabine and interferon alpha seems to be effective and well tolerated in patients with advanced SCC. Controlled trials are necessary to prove the benefit we observed in this case series.
Literatur
1.
Zurück zum Zitat Armstrong BK, Kricker A (2001) The epidemiology of UV-induced skin cancer. J Photochem Photobiol B 63:8–18CrossRef Armstrong BK, Kricker A (2001) The epidemiology of UV-induced skin cancer. J Photochem Photobiol B 63:8–18CrossRef
2.
Zurück zum Zitat Arnold SM, Regine WF, Ahmed MM, Valentino J, Spring P, Kudrimoti M, Kenady D, Desimone P, Mohiuddin M (2004) Low-dose fractionated radiation as a chemopotentiator of neoadjuvant paclitaxel and carboplatin for locally advanced squamous cell carcinoma of the head and neck: results of a new treatment paradigm. Int J Radiat Oncol Biol Phys 58:1411–1417CrossRef Arnold SM, Regine WF, Ahmed MM, Valentino J, Spring P, Kudrimoti M, Kenady D, Desimone P, Mohiuddin M (2004) Low-dose fractionated radiation as a chemopotentiator of neoadjuvant paclitaxel and carboplatin for locally advanced squamous cell carcinoma of the head and neck: results of a new treatment paradigm. Int J Radiat Oncol Biol Phys 58:1411–1417CrossRef
3.
Zurück zum Zitat Bell KA, Perna AG, Hsu S (2001) Mucositis as a treatment-limiting side effect in the use of capecitabine for the treatment of metastatic breast cancer. J Am Acad Dermatol 45:790–791CrossRef Bell KA, Perna AG, Hsu S (2001) Mucositis as a treatment-limiting side effect in the use of capecitabine for the treatment of metastatic breast cancer. J Am Acad Dermatol 45:790–791CrossRef
4.
Zurück zum Zitat Cartei G, Cartei F, Interlandi G, Meneghini G, Jop A, Zingone G, Tabaro G, Mazzoleni F (2000) Oral 5-fluorouracil in squamous cell carcinoma of the skin in the aged. Am J Clin Oncol 23:181–184CrossRef Cartei G, Cartei F, Interlandi G, Meneghini G, Jop A, Zingone G, Tabaro G, Mazzoleni F (2000) Oral 5-fluorouracil in squamous cell carcinoma of the skin in the aged. Am J Clin Oncol 23:181–184CrossRef
5.
Zurück zum Zitat Chang DZ, Olencki T, Budd GT, Peereboom D, Ganapathi R, Osterwalder B, Bukowski R (2001) Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokinetics. Cancer Chemother Pharmacol 48:493–498CrossRef Chang DZ, Olencki T, Budd GT, Peereboom D, Ganapathi R, Osterwalder B, Bukowski R (2001) Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokinetics. Cancer Chemother Pharmacol 48:493–498CrossRef
6.
Zurück zum Zitat Czarnecki D, Meehan CJ, Bruce F, Culjak G (2002) The majority of cutaneous squamous cell carcinomas arise in actinic keratoses. J Cutan Med Surg 6:207–209 Czarnecki D, Meehan CJ, Bruce F, Culjak G (2002) The majority of cutaneous squamous cell carcinomas arise in actinic keratoses. J Cutan Med Surg 6:207–209
7.
Zurück zum Zitat Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H (1998) Positive correlation between the effect of capecitabine and deoxyfluorodine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumor in human cancer xenografts. Cancer Res 58:685–690 Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H (1998) Positive correlation between the effect of capecitabine and deoxyfluorodine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumor in human cancer xenografts. Cancer Res 58:685–690
8.
Zurück zum Zitat Johnston PG, Kaye S (2001) Capecitabine: a novel agent for the treatment of solid tumors. Anticancer Drugs 12:639–646CrossRef Johnston PG, Kaye S (2001) Capecitabine: a novel agent for the treatment of solid tumors. Anticancer Drugs 12:639–646CrossRef
9.
Zurück zum Zitat Khansur T, Allred C, Little D, Anand V (1995) Cisplatin and 5-fluorouracil for metastatic squamous cell carcinoma from unknown primary. Cancer Invest 13:263–266 Khansur T, Allred C, Little D, Anand V (1995) Cisplatin and 5-fluorouracil for metastatic squamous cell carcinoma from unknown primary. Cancer Invest 13:263–266
10.
Zurück zum Zitat Lewis KG, Lewis MD, Robinson-Bostom L, Pan TD (2004) Inflammation of actinic keratoses during capecitabine therapy. Arch Dermatol 140:367–368CrossRef Lewis KG, Lewis MD, Robinson-Bostom L, Pan TD (2004) Inflammation of actinic keratoses during capecitabine therapy. Arch Dermatol 140:367–368CrossRef
11.
Zurück zum Zitat McGavin JK, Goa KL (2001) Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer. Drugs 61:2309–2326 McGavin JK, Goa KL (2001) Capecitabine: a review of its use in the treatment of advanced or metastatic colorectal cancer. Drugs 61:2309–2326
12.
Zurück zum Zitat Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K et al (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274–1281CrossRefPubMed Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K et al (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34:1274–1281CrossRefPubMed
13.
Zurück zum Zitat Mori K, Hasegawa M, Nishida M, Toma H, Fukuda M, Kubota T, et al (2000) Expression levels of thymidine phosphorylase and dihydro-pyrimidine dehydrogenase in various human tumor tissues. Int J Oncol 17:33–38PubMed Mori K, Hasegawa M, Nishida M, Toma H, Fukuda M, Kubota T, et al (2000) Expression levels of thymidine phosphorylase and dihydro-pyrimidine dehydrogenase in various human tumor tissues. Int J Oncol 17:33–38PubMed
14.
Zurück zum Zitat Morita T, Matsuzaki A, Suzuki K, Tokue A (2001) Role of thymidine phosphorylase in biomodulation of fluoropyrimidines. Curr Pharm Biotechnol 2:257–267 Morita T, Matsuzaki A, Suzuki K, Tokue A (2001) Role of thymidine phosphorylase in biomodulation of fluoropyrimidines. Curr Pharm Biotechnol 2:257–267
15.
Zurück zum Zitat Motley R, Kersey P, Lawrence C on behalf of the British Association of Dermatologists, the British Association of Plastic Surgeons & the Faculty of Clinical Oncology of the Royal College of Radiologists (2002) Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma. Br J Dermatol 146:18–25CrossRef Motley R, Kersey P, Lawrence C on behalf of the British Association of Dermatologists, the British Association of Plastic Surgeons & the Faculty of Clinical Oncology of the Royal College of Radiologists (2002) Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma. Br J Dermatol 146:18–25CrossRef
16.
Zurück zum Zitat O’Shaughnessy J (2002) Clinical experience of capecitabine in metastatic breast cancer. Eur J Cancer 38 [Suppl 2]:10–14 O’Shaughnessy J (2002) Clinical experience of capecitabine in metastatic breast cancer. Eur J Cancer 38 [Suppl 2]:10–14
17.
Zurück zum Zitat Pivot X, Chamorey E, Guardiola E, Magne N, Thyss A, Otto J, Giroux B, Mouri Z, Schneider M, Milano G (2003) Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients. Ann Oncol 14:1578–1586CrossRef Pivot X, Chamorey E, Guardiola E, Magne N, Thyss A, Otto J, Giroux B, Mouri Z, Schneider M, Milano G (2003) Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients. Ann Oncol 14:1578–1586CrossRef
18.
Zurück zum Zitat Sadek H, Azli N, Wendling JL, Cvitkovic E, Rahal M, Mamelle G et al (1990) Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer 66:1692–1696 Sadek H, Azli N, Wendling JL, Cvitkovic E, Rahal M, Mamelle G et al (1990) Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer 66:1692–1696
19.
Zurück zum Zitat Seegenschmiedt MH (1998) Interdisciplinary documentation of treatment side effects in oncology. Present status and perspectives. Strahlenther Onkol 174 [Suppl 3]:25–29 Seegenschmiedt MH (1998) Interdisciplinary documentation of treatment side effects in oncology. Present status and perspectives. Strahlenther Onkol 174 [Suppl 3]:25–29
20.
Zurück zum Zitat Therasse P, Arbruck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216CrossRefPubMed Therasse P, Arbruck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216CrossRefPubMed
21.
Zurück zum Zitat Ventirini M (2000) Rational development of capecitabine. Eur J Cancer 38 [Suppl 2]:3–9 Ventirini M (2000) Rational development of capecitabine. Eur J Cancer 38 [Suppl 2]:3–9
22.
Zurück zum Zitat Yates JW, Chalmer B, McKegney FP (1980) Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 45:2220–2224 Yates JW, Chalmer B, McKegney FP (1980) Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 45:2220–2224
Metadaten
Titel
Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin
verfasst von
Uwe Wollina
Gesina Hansel
Andreas Koch
Erich Köstler
Publikationsdatum
01.05.2005
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 5/2005
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-004-0656-6

Weitere Artikel der Ausgabe 5/2005

Journal of Cancer Research and Clinical Oncology 5/2005 Zur Ausgabe

Letter to the Editor

Treosulfan and gemcitabine

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.